



Is It Time for a Thai Cancer Drug Fund? From Global Evidence to Collaborative Action – A Response to Recent Commentary

Parnnaphat Luksameesate¹, Osot Nerapusee², Chanthawat Patikorn¹, Puree Anantachoti^{1*}

*Correspondence to: Puree Anantachoti, Email: Puree.a@pharm.chula.ac.th

Copyright: © 2026 The Author(s); Published by Kerman University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation: Luksameesate P, Nerapusee O, Patikorn C, Anantachoti P. Is it time for a Thai cancer drug fund? From global evidence to collaborative action – a response to recent commentary. *Int J Health Policy Manag.* 2026;15:10127. doi:10.34172/ijhpm.10127

Received: 7 July 2026; Accepted: 17 July 2026; ePublished: 22 July 2026

We would like to thank Dr. Jong Hyuk Lee for his insightful commentary on our study, “Scoping Review of International Experience of a Dedicated Fund to Support Patient Access to Cancer Drugs: Policy Implications for Thailand.”¹ His highlights on balancing innovation, affordability, and equity provide an invaluable extension to our policy recommendations and open up crucial pathways for structural refinement.² Below, we address the specific methodological points raised and further contextualize the operational, social, and fiscal dimensions within Thailand’s current healthcare landscape.

Addressing Methodological and Data Points

We highly appreciate Lee’s thorough review of the data. Regarding the specific figures, such as the number of covered cancer drugs under England’s Cancer Drugs Fund (CDF) standing at 102 instead of 95, we acknowledge that his data reflected the updated status at that specific time point. The figures presented in our original article were bounded by the data collection timeframe of 2022–2023. Furthermore, we agree with Lee’s assertion regarding the importance of local-language official documents and grey literature in capturing nuanced regulatory mechanisms. Our review indeed incorporated both published and grey literature to minimize translation and interpretation biases across jurisdictions.

The Thai Context: Fragmentation and Unmet Medical Needs

To understand the necessity of a ring-fenced CDF and managed entry agreements in Thailand, the structural characteristics of its healthcare system must be examined.

Nominally, 100% of the Thai population has been covered under three major public health insurance schemes since 2002: the universal coverage scheme, the social security scheme, and the civil servant medical benefit scheme.³ Patients incur no out-of-pocket costs for medications listed within the core benefits package. While all three schemes share the same National List of Essential Medicines (NLEM) as their baseline, their historical origins differ, allowing each scheme to independently expand certain benefits. For instance, the Civil Servant Medical Benefit Scheme operates the Outpatient Cancer Prior Authorization program allow expansion of certain cancer drugs under restricted conditions.⁴

Despite these provisions, a significant policy gap persists. Numerous innovative medicines remain excluded from the NLEM, often taking several years (until generics or stand-alone biologics emerge) to be integrated.⁵ Oncology and rare diseases represent the areas with the highest unmet medical needs, where high treatment costs expose citizens to catastrophic health expenditure.⁶ The NLEM relies strictly on health technology assessment (HTA) frameworks, applying an incremental cost-effectiveness ratio threshold of 160 000 Baht per quality-adjusted life-year alongside rigorous budget impact analyses. Consequently, innovative cancer therapies—with incremental cost-effectiveness ratios exponentially exceeding this threshold—are structurally blocked from routine reimbursement, leaving patients financially vulnerable.^{4,7}

Stakeholder Consensus and Operational Governance

As researchers, we argue for a philosophical pivot in insurance design, moving toward protecting against catastrophic illness, establishing shared responsibilities, and introducing complementary mechanisms, such as a CDF, to safeguard access to life-saving treatments without replacing Thailand’s existing HTA and NLEM processes. Following our scoping review, we presented international evidence on CDFs and managed entry agreements to key stakeholders, culminating in stakeholder consensus meetings to explore local feasibility. The majority of stakeholders agreed that a Thai CDF is feasible but demanded absolute clarity on several operational parameters to guarantee evidence-based, fair, and transparent implementation⁸:

1. Equity across schemes: The CDF must provide uniform

access across all three public health insurance schemes to eliminate disparities.

2. Targeted scope: The fund must explicitly prioritize life-saving and practice-changing medicines that fail standard NLEM approval due to lack of cost-effectiveness or excessive budget impact.
3. Optimized selection process: To minimize administrative delays, the drug selection process should seamlessly follow the NLEM evaluation pipeline. If a drug fails the routine HTA pathway, it should be immediately screened for CDF eligibility based on refined criteria, which need to be developed and explored their practicality in Thailand.
4. Governance and infrastructure: Developing explicit CDF budget estimation models, public accountability mechanisms, and robust real-world evidence infrastructure is vital for monitoring and evaluation. Legal and regulatory frameworks must also be amended to accommodate manufacturer rebates.

Public Perceptions and Future Policy Directions (2025–2027)

To address the critical attribute of “shared responsibility” and understand public tolerance toward financial risk-pooling, our research team conducted a qualitative study between 2025 and 2026. Through in-depth interviews across beneficiaries of all three insurance schemes spanning four distinct household income levels, we made a striking finding: Thai citizens across all socio-economic strata expressed a willingness to share financial responsibility for minor illnesses, chronic diseases, and even severe conditions, provided that robust safety nets are established. However, their actual financial capacity varies significantly by income and disease severity.

Moving forward, our team has initiated the development of explicit drug selection criteria tailored for the Thai CDF. This collaborative refinement process with clinical experts and policy stakeholders is projected for completion in 2027. Amid tight national fiscal constraints, our framework recommends that the CDF prioritize drugs with robust evidence of meaningful clinical benefit while ensuring a transparent and evidence-based selection process. Operationally, the CDF should primarily focus on improving timely patient access.

Conclusion

A well-structured, managed-access fund must align seamlessly with Thailand's socio-economic realities. The continuous academic exchange between our findings and his commentary serves as a crucial cornerstone for policy-makers, bridging the gap among innovation, affordability, and equity in cancer care.

Disclosure of artificial intelligence (AI) use

- Section(s) of manuscript affected: The entire manuscript (overall language

editing and proofreading).

- Type of AI tool(s) used: Gemini (Google).
- Purpose of use: AI was strictly only use for language editing, grammatical corrections, and proofreading to improve clarity and readability.

Ethical issues

Not applicable.

Conflicts of interest

Authors declare that they have no conflicts of interest.

Disclaimer

The opinions expressed in this paper are authors's opinion and do not represent the views of their institutions or other stakeholders.

Authors' contributions

Conceptualization: Parnnaphat Luksameesate, Osot Nerapusee, Chanthawat Patikorn, and Puree Anantachoti.

Supervision: Puree Anantachoti.

Validation: Parnnaphat Luksameesate, Osot Nerapusee, Chanthawat Patikorn, and Puree Anantachoti.

Writing—original draft: Parnnaphat Luksameesate and Puree Anantachoti.

Writing—review & editing: Parnnaphat Luksameesate, Osot Nerapusee, Chanthawat Patikorn, and Puree Anantachoti.

Authors' affiliations

¹Social and Administrative Pharmacy Department, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. ²School of Pharmacy, Eastern Asia University, Pathum Thani, Thailand.

References

1. Luksameesate P, Nerapusee O, Patikorn C, Anantachoti P. Scoping review of international experience of a dedicated fund to support patient access to cancer drugs: policy implications for Thailand. *Int J Health Policy Manag.* 2024;13:7768. doi:10.34172/ijhpm.2023.7768
2. Lee JH. Establishing a dedicated fund to improve patient access to cancer medicines: key considerations and policy implications for Thailand: Comment on “Scoping review of international experience of a dedicated fund to support patient access to cancer drugs: policy implications for Thailand.” *Int J Health Policy Manag.* 2025;14:9153. doi:10.34172/ijhpm.9153
3. Sakulbumrungsil R, Kessomboon N, Kanchanapibool I, et al. The impact of drug financing system under Thailand universal health coverage (UHC) on the performances of drug system. *Journal of Health Science of Thailand.* 2020;29:S59-S71.
4. Patikorn C, Taychakoonavudh S, Thathong T, Anantachoti P. Patient access to anti-cancer medicines under public health insurance schemes in Thailand: A mixed methods study. *Thai Journal of Pharmaceutical Sciences.* 2019;43(3):168-178.
5. Taychakoonavudh S, Phoolcharoen W, Pesirikan N, et al. The landscape of biologics drug system in Thailand. *Journal of Health Science of Thailand.* 2020;29:S96-S111.
6. Kaso AW, Regesu AH, Haftu HK, et al. Magnitude of catastrophic health expenditure and its determinants among cancer patients in low and middle-income countries: a systematic review and meta-analysis. *BMC Health Serv Res.* 2025;25(1):1533. doi:10.1186/s12913-025-13723-4
7. Ungtrakul T, Siripaibun J, Anantachoti P, et al. Exploring alternative funding mechanisms to improve patient access to innovative medicines. *BMC Health Services Research.* 2026;26(1):644. doi:10.1186/s12913-026-14438-w
8. Chulalongkorn University, Chulabhorn Royal Academy. Feasibility of Implementing Cancer Drugs Fund in Thailand. <https://online.pubhtml5.com/vyjq/hvdv/>. Accessed June 15, 2026. Published 2025.